At a glance
ClinicalIndex Comparison Record- ✓Metastatic or unresectable clear cell renal cell carcinoma confirmed by biopsy
- ✓Previous nephrectomy is required
- ✓Maximum of 1 previous systemic regimen for metastatic disease
- ✓Able to perform activities of daily living with minimal assistance
- ✕Age less than 18 years
- ✕Treatment with more than 1 previous systemic regimen
- ✕History of heart attack within 6 months
- ✕Clinically significant cardiovascular disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Erlotinib, and 1 other intervention for Clear Cell Renal Cell Carcinoma. Completed, enrolled 94 participants.
Detailed Summary
This phase I/II trial will evaluate the bevacizumab/erlotinib combination with the addition of imatinib (Gleevec). The combined inhibition greatly enhances the anti-tumor effects. Although the safety of the bevacizumab/erlotinib/imatinib combination has not yet been demonstrated, the mild to moderate side effects of all of these agents are not predicted to cause prohibitive toxicity. A brief phase I portion will be included in this trial, to optimize doses of the 3 agents prior to proceeding with the phase II trial.
Study Details
Timeline
Interventions
10mg/kg IV infusion every 2 weeks
150 mg po daily
400-600mg daily